Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Boehringer Ingelheim may have been on a spending spree for licensing deals so far this year—but the German pharma has plenty ...

After securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million last year, peptide drug ...

The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. | The ...

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...

After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the ...

Ferring Pharmaceuticals is halting work on two trials of a phase 1 infertility candidate that together had enrolled 416 ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...

Another phase 3 trial, Chestnut, evaluated children who switched from Strensiq to efzimfotase alfa. The study showed ...